Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16082067 | 0.72 | GLA (0.34) | GLATSHR | |
| SCHEMBL21324849 | 0.70 | L3MBTL1 (0.57) | L3MBTL1DAO | |
| SCHEMBL19403690 | 0.70 | HPGD (0.36) | GLATSHRDAOBTKHPGD | |
| SCHEMBL18269679 | 0.69 | MEN1 (0.43) | GLATSHRDAO | |
| SCHEMBL23225408 | 0.64 | GLA (0.34) | GLATSHR | |
| SCHEMBL13233284 | 0.64 | GLA (0.54) | GLATSHR | |
| SCHEMBL166882 | 0.63 | — | — | |
| SCHEMBL17189455 | 0.61 | L3MBTL1 (0.52) | L3MBTL1 | |
| SCHEMBL84555 | 0.60 | PTGS1 (0.43) | L3MBTL1 | |
| SCHEMBL814784 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239809-A1 | THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION | ARTUS THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20230193231-A1 | ENGINEERED GENE-EDITING PROTEINS | FACTOR BIOSCIENCE INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230111853-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | ORIONIS BIOSCIENCES, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20220169611-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2022-06-02 | — | — | US | disclosed |
| US-11053251-B2 | GPR35 modulators | PROMETHEUS BIOSCIENCES, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20210179560-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210009505-A1 | CATIONIC LIPIDS AND TRANSFECTION METHODS | FACTOR BIOSCIENCE INC. | 2021-01-14 | — | — | US | disclosed |
| US-20200239476-A1 | GPR35 MODULATORS | PROMETHEUS BIOSCIENCES, INC. | 2020-07-30 | — | — | US | disclosed |
| US-20190133976-A1 | METABOLICALLY ROBUST ANALOGS OF CYP-EICOSANOIDS FOR THE TREATMENT OF CARDIAC DISEASE | OMEICOS THERAPEUTICS GMBH (DE) | 2019-05-09 | — | — | US | disclosed |
| US-10005740-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-06-26 | — | — | US | disclosed |
| US-20070149810-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149810-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070106095-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070106095-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| EP-0471092-B1 | TRIAZOLE COMPOUND AND INSECTICIDE | SDS BIOTECH CORP (JP) | 1995-09-27 | — | — | EP | disclosed |
| US-5286738-A | Nematocides | S.D.S. BIOTECH K.K. (JP) | 1994-02-15 | — | — | US | disclosed |
| US-5208231-A | Dialkylcarbamoyl substituted compounds | S.D.S. BIOTECH K.K. (JP) | 1993-05-04 | — | — | US | disclosed |
| US-5155124-A | TRIAZOLE COMPOUND AND INSECTICIDE COMPOSITION CONTAINING THE SAME | S.D.S. BIOTECH K.K. (JP) | 1992-10-13 | — | — | US | disclosed |
| EP-0471092-A1 | TRIAZOLE COMPOUND AND INSECTICIDE | S.D.S. BIOTECH K.K. (JP) | 1992-02-19 | — | — | EP | disclosed |
| EP-0399553-A1 | Triazole compound and insecticide composition containing the same | SDS Biotech K.K. (JP) | 1990-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230111853-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | CRBN, STUB1, ADRM1 | L3MBTL1 2188/4885GLA 3096/4885TSHR 3805/4885 |
| US-20220169611-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | L3MBTL1 3993/4885GLA 2345/4885TSHR 4432/4885 |
| US-11053251-B2 | GPR35 modulators | GPR35, GPR55, GPR65 | L3MBTL1 4058/4885GLA 2411/4885TSHR 1618/4885 |
| US-20210179560-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | L3MBTL1 3993/4885GLA 2345/4885TSHR 4432/4885 |
| US-20070106095-A1 | Vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | L3MBTL1 4455/4885GLA 2712/4885TSHR 602/4885 |
| US-10005740-B2 | Neprilysin inhibitors | MME, REN, AGTR1 | L3MBTL1 2162/4885GLA 502/4885TSHR 1044/4885 |
| US-20070149810-A1 | Vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | L3MBTL1 4181/4885GLA 3433/4885TSHR 387/4885 |
| US-20240239809-A1 | THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION | LIPG, FABP2, EPCAM | L3MBTL1 4597/4885GLA 1193/4885TSHR 4301/4885 |
| US-20190133976-A1 | METABOLICALLY ROBUST ANALOGS OF CYP-EICOSANOIDS FOR THE TREATMENT OF CARDIAC DISEASE | ALOX5, ALOX15, ALOX15B | L3MBTL1 3867/4885GLA 957/4885TSHR 2377/4885 |
| US-20200239476-A1 | GPR35 MODULATORS | GPR35, GPR55, GPR65 | L3MBTL1 4058/4885GLA 2411/4885TSHR 1618/4885 |
| US-20210009505-A1 | CATIONIC LIPIDS AND TRANSFECTION METHODS | CETP, NPC1L1, NPC1 | L3MBTL1 566/4885GLA 2890/4885TSHR 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.